Climb Bio (CLYM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.18
- Estimate
- -$0.21
- Surprise
- +15.3%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Climb Bio (CLYM) reported a narrower loss than forecast — diluted EPS of -$0.18 against the -$0.21 estimate (a 15.3% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CLYM Sell at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +15.3% surprise compares with a -1.6% four-quarter average. Next scheduled report: 2026-11-13.
What argues against it
- Concentration risk — Pipeline: budoprutug and CLYM116 (entire clinical pipeline)
- Concentration risk — Counterparty: product candidate licensors (including Mabworks)
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.48
- Price target
- $23.99
- Stop
- $13.25
- Upside to target
- +65.7%
- Reward-to-risk
- 4.6:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
CLYM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $818.5M
- P/E (fwd)
- -14.2
- 52-week range
- $1.54–$18.33
- Off 52-week high
- 21.0%
- RSI (14)
- 36
- Volume vs avg
- 0.84×
- Score today
- 5.6/10